Visão geral do mercado

The Microneedle Drug Delivery Systems Market is projected to witness substantial growth, increasing from USD 2,808 million in 2023 to USD 3,908 milhão por 2028, at a Compound Annual Growth Rate (CAGR) of 6.83% during the forecast period (2023-2028).

A microneedle drug delivery system serves as a non-invasive and painless transdermal drug delivery system used for administering drugs and vaccines. Microneedles create temporary, micron-sized pores on the skin, enabling the delivery of drugs and vaccines.

Several factors are contributing to the growth of the market, including the increasing prevalence of chronic diseases and lifestyle-related disorders, advancements in painless drug delivery research, technological progress, and the growing demand for safer alternatives to traditional hypodermic injections.

The rise in chronic diseases worldwide is fueling the demand for advanced drug delivery systems, driving market growth. For example, in England, around 6.4 million people were living with cardiovascular diseases in 2021, and the United Kingdom was projected to have approximately 7.4 million people living with heart and circulatory diseases in the same year. The high number of people with cardiovascular diseases necessitates controlled or slow drug release, driving market growth.

Similarly, diabetes is a significant concern, with approximately 537 million individuals suffering from the condition in 2021, projected to increase to 643 milhão por 2030 e 784 milhão por 2045. The growing diabetic population is driving demand for microneedle technology to deliver insulin in a minimally invasive and painless manner, supporting market growth.

Research studies focusing on microneedle drug delivery are also contributing to its adoption in various medical applications. For example, microelectromechanical system (MEMS)-based microneedles have shown promise in enhancing drug permeability through microscopic pores in the skin. The effectiveness of microneedles in facilitating drug diffusion and dermal microcirculation is expected to drive market growth.

Furthermore, increasing company activities in developing microneedle products and launching new products are driving market growth. For instance, Zosano Pharma reported positive clinical data showing the effectiveness of its transdermal microneedle system for delivering a trivalent influenza vaccine, comparable to the traditional injected vaccine.

The Microneedle Drug Delivery Systems Market is expected to grow during the forecast period due to factors such as the rising burden of chronic diseases, the increasing adoption of microneedle drug delivery systems, and ongoing research in painless drug delivery. However, market growth may face limitations due to the limited number of approved products and potential complications associated with microneedles.

Segmentação de mercado

The market is segmented based on various factors, including product type, application, and geography.

Segmentation by Product Type
Solid
Hollow
Coated
Dissolvable

Segmentation by Application
Drug Delivery
Vaccine Delivery
Dermatology
Other Applications

Segmentation by Geography
North America – Estados Unidos, Canadá, and Mexico
Europe – Reino Unido, Alemanha, França, Itália, Espanha, and Rest of Europe
Asia-Pacific – China, Japão, South Korea, Índia, Austrália, and Rest of Asia-Pacific
Rest of the World

The microneedle drug delivery market is anticipated to experience significant growth in the vaccine delivery segment over the forecast period. This growth can be attributed to several factors, including the increasing prevalence of influenza and viral infections, as well as the efforts of key players in the research and development of microneedle vaccines. For example, the National Center for Disease Control (NCDC) of India reported a substantial rise in seasonal influenza (H1N1) cases in 2022 compared to the previous year, indicating a growing demand for microneedle vaccines to address such infections.

Além disso, studies have shown that microneedle vaccinations can elicit a robust immune response against various viral and bacterial infections due to their ability to efficiently deliver vaccines to the epidermis and dermis regions, where immune cells are abundant. The use of sustained-release polymers or integrated microparticles and nanoparticles in microneedles has the potential to eliminate the need for multiple vaccinations, further bolstering the demand for such vaccine delivery systems.

Additionally, the increasing focus of companies on adopting various business strategies, such as mergers and collaborations, coupled with a rise in vaccine launches, is expected to contribute to the growth of the vaccine delivery segment. Notable examples include Vaxess Technologies establishing a manufacturing facility for its sustained-release intradermal microneedle patch and Microdermics, Inc. merging with Novateur Ventures to commercialize a new microneedle flu vaccine and biosensing platform.

Furthermore, the market for microneedle drug delivery systems in North America is poised for significant growth due to the rising prevalence of chronic diseases, skin diseases, and infectious diseases. The region has witnessed considerable technological advancements in drug delivery systems, particularly in the fabrication of microneedles, which further promotes their adoption. The increasing burden of chronic diseases, such as brain tumors and heart disease, is expected to drive the demand for microneedle drug delivery technology in the region.

Additionally, the high number of flu cases in the United States is likely to fuel demand for microneedles coated with influenza viruses to elicit protective immunity. The region also benefits from various strategic initiatives adopted by companies, such as collaborations, partnerships, and agreements, which are expected to contribute to market growth. Notable examples include the launch of self-dissolving microneedle patches by Wrinkles Schminkles and the co-development agreement signed between PharmaTher and TSRL for a microneedle array patch.

In conclusion, the microneedle drug delivery market, particularly the vaccine delivery segment, is anticipated to grow significantly over the forecast period due to factors such as the increasing prevalence of infectious diseases, technological advancements in drug delivery systems, and strategic initiatives by companies.

Cenário competitivo

The market for microneedle drug delivery systems is characterized by fragmentation and high competition, with the presence of several significant players. At present, a few of these major players hold a dominant position in terms of market share.

Key companies profiled in this report include Candela Corporation, Becton, Dickinson and Company, Raphas Co. Ltda, NanoPass Technologies Limited, Corium Inc., Debiotech SA, CosMED Pharmaceutical Co. Ltda, NanoBioSciences LLC, Micropoint Technologies, LTS Lohmann Therapie-Systeme AG.

Recent Industry Developments

In November 2022, CGBio, a healthcare provider based in South Korea, introduced a new skin trouble care patch named CGDew Derma Regen, as part of its microneedle pipeline. These innovative microneedle patches are crafted from a variety of materials, including silicon, titanium, stainless steel, and polymers. Their purpose is to enhance the diffusivity of medications to the stratum corneum by creating minute pores on the skin, each smaller than a micron.

During October 2022, Emergex Vaccines Holding Limited successfully acquired the assets of Zosano Pharma Corporation. These assets encompass a valuable array of intellectual property, license agreements, manufacturing equipment, and Zosano’s proprietary microneedle array patch (MAP) intradermal drug delivery system. Additionally, the acquisition included the rights to solid-coated microneedle array patch technology, methods for formulation and microneedle coating, and specialized equipment.

Key Questions Answered

What is the study period of the Microneedle Drug Delivery Systems Market?
The study period of the Microneedle Drug Delivery Systems Market is from 2018 to 2028.

What is the growth rate of the Microneedle Drug Delivery Systems Market?
The Microneedle Drug Delivery Systems Market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.83% over the next five years.

What is the size of the Microneedle Drug Delivery Systems Market?
The Microneedle Drug Delivery Systems Market is expected to reach USD 2,808 million in 2023 and is projected to grow at a CAGR of 6.83% to reach USD 3,908 milhão por 2028.

Which region has the highest growth rate in the Microneedle Drug Delivery Systems Market?
The Asia-Pacific region is experiencing the highest CAGR growth over the period 2018 to 2028.

Which region has the largest share in the Microneedle Drug Delivery Systems Market?
North America holds the highest market share in 2022.

Who are the key players in the Microneedle Drug Delivery Systems Market?
The major companies operating in the Microneedle Drug Delivery Systems Market include Becton, Dickinson and Company, Raphas Co. Ltd., Nanopass Technologies, Corium Inc., and Nitto Denko Corporation.